Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study

Anita R. Peoples, University of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA
Peter W. Bushunow, Rochester Regional HealthFollow
Sheila N. Garland, Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.
Charles E. Heckler, University of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Joseph A. Roscoe, University of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Luke L. Peppone, University of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Deborah J. Dudgeon, Palliative Care Medicine, Department of Internal Medicine, Queen's University, Kingston, ON, Canada.
Jeffrey J. Kirshner, HOACNY CCOP, 5008 Brittonfield Parkway, Suite #700, PO Box 2050, East Syracuse, NY, 13057, USA.
Tarit K. Banerjee, Marshfield CCOP, Marshfield Clinic, 1000 N. Oak Avenue, 2R-1 Lawton Center, Marshfield, WI, 54449, USA.
Judith O. Hopkins, Southeast Cancer Control consortium, 2150 Country Club Road, Suite 200, Winston-Salem, NC, 27104, USA.
Shaker R. Dakhil, Wichita CCOP, 929 North St. Frances, Wichita, KS, 67214, USA.
Marie A. Flannery, University of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Gary R. Morrow, University of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.

Department

Oncology and Hematology

Document Type

Article

Publication Title

Supportive Care in Cancer

Abstract

PURPOSE: Cancer-related dyspnea is a common, distressing, and difficult-to-manage symptom in cancer patients, resulting in diminished quality of life and poor prognosis. Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has proven efficacy in the treatment of generalized anxiety disorder, has been suggested to relieve the sensation of dyspnea in patients with COPD. The main objective of our study was to evaluate whether buspirone alleviates dyspnea in cancer patients. METHODS: We report on a randomized, placebo-controlled trial of 432 patients (mean age 64, female 51%, lung cancer 62%) from 16 participating Community Clinical Oncology Program (CCOP) sites with grade 2 or higher dyspnea, as assessed by the Modified Medical Research Council Dyspnea Scale. Dyspnea was assessed by the Oxygen Cost Diagram (OCD; higher scores are better) and anxiety by the state subscale of the State-Trait Anxiety Inventory (STAI-S; lower scores are better) at baseline and after the 4-week intervention (post-intervention). RESULTS: Mean scores from baseline to post-intervention for buspirone were OCD 8.7 to 9.0 and STAI-S 40.5 to 40.1 and for placebo were OCD 8.4 to 9.3 and STAI-S 40.9 to 38.6 with raw improvements over time on both measures being greater in the placebo group. Analysis of covariance (ANCOVA) controlling for baseline scores showed no statistically significant difference between groups for OCD (P = 0.052) or STAI-S (P = 0.062). CONCLUSION: Buspirone did not result in significant improvement in dyspnea or anxiety in cancer patients. Thus, buspirone should not be recommended as a pharmacological option for dyspnea in cancer patients.

First Page

1339

Last Page

47

DOI

10.1007/s00520-015-2903-6

Volume

24

Issue

3

Publication Date

3-1-2016

Medical Subject Headings

Anti-Anxiety Agents (administration & dosage, therapeutic use); Anxiety (drug therapy); Anxiety Disorders (diagnosis); Buspirone (administration & dosage, therapeutic use); Disease Management; Double-Blind Method; Dyspnea (drug therapy); Female; Humans; Male; Middle Aged; Neoplasms (complications, drug therapy); Quality of Life

PubMed ID

26329396

Link to Full Text

Share

COinS